A Special Protocol Assessment is an FDA procedure that lets a drug or biologic sponsor obtain the agency’s written agreement, before a trial begins, that the study’s design and planned analyses are adequate to support a future marketing application. The agreement is codified at section 505(b)(5)(B) of the Federal Food, Drug, and Cosmetic Act and binds both the sponsor and the FDA once the trial starts, with narrow exceptions.1Office of the Law Revision Counsel. 21 USC 355 – New Drugs Used well, it removes one of the biggest risks in drug development: running an expensive trial only to hear later that the FDA never considered the design capable of supporting approval.
Which Studies Qualify
The FDA limits the tool to studies that carry the highest regulatory stakes because they will form the primary basis of an effectiveness claim in a New Drug Application (NDA) or Biologics License Application (BLA). Four categories are eligible:2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry
- Phase 3 clinical trials intended to form the primary basis of an effectiveness claim.
- Animal carcinogenicity protocols.
- Stability protocols for a drug substance or drug product.
- Animal efficacy protocols conducted under the Animal Rule, used when human efficacy trials would be unethical or impractical.
For biosimilar products seeking approval under section 351(k) of the Public Health Service Act, any clinical study necessary to demonstrate biosimilarity may also qualify.1Office of the Law Revision Counsel. 21 USC 355 – New Drugs Early-phase exploratory studies and trials outside these categories fall outside the process.
What to Include in the Request
A complete submission gives reviewers everything they need in one package. A half-finished one stalls the review or draws a refusal to file. Include:2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry
- The full trial protocol, covering study objectives, patient population, dose selection, endpoints, and the statistical analysis plan.
- Specific, focused questions for the FDA about critical protocol features such as enrollment criteria, primary efficacy and safety endpoints, dose range, and known limitations of the design. Vague questions slow the review.
- A summary of any relevant prior FDA interactions, such as End-of-Phase 2 or pre-Phase 3 meeting minutes, so reviewers see how the design evolved.
- Manufacturing and formulation information confirming that the clinical supply does not differ substantively from the product intended for market.
The cover letter must identify the submission as a “Request for Special Protocol Assessment” in bolded block letters at the top and specify the type of protocol enclosed. That labeling is what routes the request correctly and starts the formal review clock.2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry
Timeline and FDA Response
The request goes electronically to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER), depending on the product. Under PDUFA and BsUFA performance goals, the FDA committed to responding within 45 calendar days of receipt.2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry There is no separate user fee; costs are covered by the broader PDUFA application and program fees sponsors already pay.3Federal Register. Prescription Drug User Fee Rates for Fiscal Year 2026
The response takes one of two forms. An Agreement letter confirms that the specified critical elements of the design are adequate. A No Agreement letter identifies specific deficiencies the sponsor needs to address.
What the Agreement Locks In
An Agreement letter means the FDA concurs that identified elements of the protocol, such as entry criteria, dose selection, endpoints, and planned analyses, are adequate and acceptable for a study intended to support a marketing application.2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry
It does not promise approval. A study conducted under an agreement can still fail. The trial may show no statistically significant benefit, or unexpected safety signals may emerge. The agreement locks in the rules of the study; it does not predetermine the result. Sponsors who read the letter as a guarantee of approval are setting themselves up for a hard surprise at the review stage.
When an Agreement Can Change After Testing Begins
Once the trial starts, an agreement can be altered only in two ways under the statute. The sponsor and the FDA can agree in writing to modify the protocol. Or the director of the reviewing division can rescind the agreement if a substantial scientific issue essential to determining the drug’s safety or effectiveness comes to light after testing starts.1Office of the Law Revision Counsel. 21 USC 355 – New Drugs That threshold is deliberately high, and the FDA guidance gives examples of what meets it:2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry
- New data calls into question the clinical relevance of the agreed efficacy endpoints.
- Safety problems emerge with the product or its broader pharmacological class.
- The FDA and the scientific community recognize a fundamental shift in how the disease is diagnosed or managed.
- Data, assumptions, or information the sponsor provided in the original submission turn out to be false, misleading, or incomplete in a way that undermines the design or patient safety.
- For programs developing a drug alongside a companion diagnostic, the diagnostic is replaced or significantly altered in a way that undermines the ability to interpret results.
The binding nature runs in both directions. A sponsor who deviates from the agreed protocol without the FDA’s written consent risks losing the protections the agreement provides, and cannot later insist the FDA honor the original terms.
Options After a No Agreement Letter
A No Agreement letter is not the end of the road. Sponsors can revise the protocol to address the specific deficiencies the FDA identified and resubmit for another round of review. The guidance is explicit that resubmissions should focus on the issues raised in the letter and should not introduce unrelated changes or new questions.2Food and Drug Administration. Special Protocol Assessment for Drugs and Biologics Guidance for Industry Treating the resubmission as a fresh start is a common way to burn a 45-day cycle without making progress.
When a sponsor believes the FDA is wrong and informal discussion has not resolved the disagreement, a formal dispute resolution path exists. The first step is working within the review division, starting with the consumer safety officer assigned to the application, and the FDA Ombudsman is available to investigate and help facilitate a resolution.4eCFR. 21 CFR 312.48 – Dispute Resolution
Beyond that, a sponsor can file a Formal Dispute Resolution Request (FDRR) to escalate above the division. Once the submission is administratively complete, the FDA has 30 days to issue a decision. If the deciding official needs more information, the clock pauses while the exchange happens. If the matter is referred to an Advisory Committee, the FDA has 30 days from receipt of the complete FDRR to place the issue on the committee’s agenda and another 30 days after the meeting to deliver a decision.5Food and Drug Administration. SOPP 8005 – Formal Dispute Resolution Process Most sponsors work hard to resolve disagreements before reaching this stage, because a formal appeal signals a breakdown in the working relationship that can affect interactions well beyond the protocol in dispute.